RxDoctor Payments Data

Mutahir Khan, MD

Cardiovascular Disease · Modesto, CANPI 1164734489

Payments from drug & device makers

$12,988in general payments, 2019–2025

Across 80 payments — averaging $162.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$11K
  • Abbott$545
  • Medtronic$412
  • Shockwave Medical, Inc$343
  • Cook Medical LLC$108
  • Edwards Lifesciences$60
  • plus $371 from 14 others

What the payments were for

  • Travel & lodging$1,39211%
  • Food & beverage$2,13416%
  • Education$120%
  • Other$9,45073%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,988 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$306,985
Medicare patients
1,064
Services billed
3,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,290$1,210,172
XareltoRivaroxaban195$194,868
BrilintaTicagrelor121$124,039
JardianceEmpagliflozin149$108,490
EntrestoSacubitril/Valsartan104$87,154
Repatha SureclickEvolocumab94$52,331
FarxigaDapagliflozin Propanediol50$35,750
MultaqDronedarone Hcl20$17,234
Metoprolol Succinate1,327$17,211
ClopidogrelClopidogrel Bisulfate745$12,062
Propafenone Hcl252$10,940
Repatha SyringeEvolocumab16$8,539
Isosorbide Dinitrate202$8,338
Losartan Potassium632$7,979
Ranolazine ErRanolazine69$7,546

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$1,210,1721,290 claims
Johnson & JohnsonXarelto$11$194,868195 claims
NovartisEntresto$45$87,154104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →